Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955182 | 1.00 | DAO (0.50) | DAOMCL1KMT2AMAPTALDH1A1 | |
| SCHEMBL6585311 | 0.88 | DAO (0.41) | DAOMCL1KMT2AMAPTALDH1A1 | |
| SCHEMBL16632907 | 0.88 | DAO (0.50) | DAOMCL1KMT2AMAPTALDH1A1 | |
| SCHEMBL17856938 | 0.80 | DAO (0.50) | DAOMCL1KMT2AMAPTALDH1A1 | |
| SCHEMBL29951155 | 0.77 | MAPT (0.49) | KMT2AMAPTMEN1 | |
| SCHEMBL3965642 | 0.77 | MAPT (0.49) | KMT2AMAPTMEN1 | |
| SCHEMBL2750570 | 0.77 | DAO (0.36) | DAOMCL1KMT2AMAPTALDH1A1 | |
| SCHEMBL1606273 | 0.76 | KDM4E (0.39) | DAOKMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL1605841 | 0.76 | CDC7 (0.38) | KMT2AMAPTKDM4E | |
| SCHEMBL29953078 | 0.76 | KDM4E (0.54) | KMT2AMAPTALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113735757-A | Microenvironment sensitive fluorescent organic small molecule compound and synthetic method and application thereof | 陕西师范大学 | 2021-12-03 | — | — | CN | claimed |
| WO-2025087274-A1 | AZABICYCLO DERIVATIVE AND PREPARATION METHOD THEREFOR, AND USE | 浙江海正药业股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| CN-115433190-B | Preparation method and application of irreversible heterocyclic compound FGFR inhibitor | 药雅科技(上海)有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20240158355-A1 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE MEDICINE (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240116878-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-04-11 | — | — | US | disclosed |
| US-20240101577-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-03-28 | — | — | US | disclosed |
| CN-113735757-B | Micro-environment sensitive fluorescent organic small molecular compound and synthetic method and application thereof | 陕西师范大学 | 2024-03-15 | — | — | CN | disclosed |
| US-20240067636-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-02-29 | — | — | US | disclosed |
| CN-111212834-B | Pyridine, pyrazine and triazine compounds as allosteric SHP2 inhibitors | 锐新医药公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-111433205-B | Polycyclic compounds as allosteric SHP2 inhibitors | 锐新医药公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2007002635-A2 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1311487-A4 | DERIVATIVES OF 1,2-DIHYDRO-7-HYDROXYQUINOLINES CONTAINING FUSED RINGS | MOLECULAR PROBES INC (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20040147747-A1 | Longer wavelength absorption than structurally similar dyes; staining; ligand and analyte detection; aromatic or heteroaromatic ring fused at 3,4-double bond | MOLECULAR PROBES, INC. | 2004-07-29 | — | — | US | disclosed |
| US-6716979-B2 | INCLUDING COUMARINS, RHODAMINES, AND RHODOLS THAT INCORPORATE ADDITIONAL FUSED AROMATIC RINGS; ABSORB AT A LONGER WAVELENGTH THAN STRUCTURALLY SIMILAR DYES THAT DO NOT POSSESS THE FUSED AROMATIC RINGS; DYE CONJUGATES; REACTIVE DYES | MOLECULAR PROBES, INC. | 2004-04-06 | — | — | US | disclosed |
| EP-1311487-A1 | DERIVATIVES OF 1,2-DIHYDRO-7-HYDROXYQUINOLINES CONTAINING FUSED RINGS | Molecular Probes Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6437138-B1 | 5-BROMO-6-CHLORO-3-(2-(S)-AZETIDINYL OR PYRROLIDINYL-METHOXY) PYRIDINE INTERMEDIATES FOR THE 5-SUBSTITUTED COMPOUNDS WHICH ARE POTENT LIGANDS AT NEURONAL NICOTINIC CHOLINERGIC CHANNEL RECEPTORS, NEUROTRANSMITTER CONTROLLING AGENTS | ABBOTT LABORATORIES | 2002-08-20 | — | — | US | disclosed |
| US-20020059684-A1 | Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings | MOLECULAR PROBES, INC. | 2002-05-23 | — | — | US | disclosed |
| WO-2002012195-A1 | DERIVATIVES OF 1,2-DIHYDRO-7-HYDROXYQUINOLINES CONTAINING FUSED RINGS | MOLECULAR PROBES, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| US-6127386-A | STIMULANTS, NEUROTRANSMITTERS, CHOLINERGIC AGENTS | ABBOTT LABORATORIES (US) | 2000-10-03 | — | — | US | disclosed |
| US-5629325-A | TREATMENT OF NERVOUS SYSTEM DISORDERS; NEURONAL NICOTINIC CHOLINERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158355-A1 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | BRDT, BRD3, BRD2 | DAO 4769/4885MCL1 2653/4885KMT2A 122/4885 |
| US-20240116878-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN22 | DAO 4167/4885MCL1 755/4885KMT2A 637/4885 |
| US-20240067636-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN1 | DAO 4429/4885MCL1 786/4885KMT2A 1272/4885 |
| US-20240101577-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPRJ | DAO 4546/4885MCL1 180/4885KMT2A 1076/4885 |
| US-20040147747-A1 | Longer wavelength absorption than structurally similar dyes; staining; ligand and analyte detection; aromatic or heteroaromatic ring fused at 3,4-double bond | CYP3A4, CYP3A5, UGT1A4 | DAO 1739/4885MCL1 3661/4885KMT2A 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.